PubRank

Claudio Trapella

Author PubWeight™ 36.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 2012 2.96
2 Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem 2006 1.13
3 Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther 2007 1.09
4 Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem 2009 1.08
5 Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 2007 1.05
6 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem 2006 1.02
7 New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem 2006 1.00
8 Triazine compounds as antagonists at Bv8-prokineticin receptors. J Med Chem 2008 0.99
9 Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem 2006 0.97
10 Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides 2010 0.97
11 Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci 2010 0.96
12 Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther 2007 0.95
13 Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol 2009 0.95
14 Synthesis and biological activity of human neuropeptide S analogues modified in position 2. J Med Chem 2008 0.95
15 Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor. J Med Chem 2007 0.94
16 Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. J Med Chem 2009 0.92
17 Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol 2009 0.92
18 The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 2007 0.90
19 Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 2008 0.90
20 Structure-activity study at positions 3 and 4 of human neuropeptide S. Bioorg Med Chem 2008 0.88
21 The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J Neurochem 2008 0.87
22 Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons. Mol Pharmacol 2010 0.86
23 Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. Eur J Neurosci 2004 0.86
24 Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Exp Neurol 2011 0.85
25 Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids. Bioorg Med Chem 2007 0.84
26 Influence of the side chain next to C-terminal benzimidazole in opioid pseudopeptides containing the Dmt-Tic pharmacophore. J Med Chem 2009 0.84
27 Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 2006 0.84
28 New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem 2006 0.83
29 Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem 2007 0.83
30 Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore. Bioorg Med Chem 2007 0.82
31 Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem 2008 0.82
32 A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem 2007 0.81
33 Glutamine vinyl ester proteasome inhibitors selective for trypsin-like (beta2) subunit. Eur J Med Chem 2007 0.78
34 A convenient route to enantiomerically pure 2-substituted methyl glycerate derivatives. Org Lett 2003 0.78
35 Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. Peptides 2008 0.78
36 Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4). Peptides 2010 0.78
37 1-Benzyl-N-[3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl]pyrrolidine-2-carboxamide (Compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaqueductal gray slices. Eur J Pharmacol 2009 0.77
38 P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors. Bioorg Med Chem Lett 2006 0.77
39 N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands. J Med Chem 2005 0.76
40 Synthesis and biological properties of C-terminal vinyl ketone pseudotripeptides. J Enzyme Inhib Med Chem 2012 0.75
41 Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). Peptides 2007 0.75
42 C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors. Eur J Med Chem 2007 0.75
43 Synthesis and activity of isoxazoline vinyl ester pseudopeptides as proteasome inhibitors. J Pept Sci 2014 0.75
44 Neuropeptide S inhibits release of 5-HT and glycine in mouse amygdala and frontal/prefrontal cortex through activation of the neuropeptide S receptor. Neurochem Int 2013 0.75
45 N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis. J Med Chem 2014 0.75
46 C-terminal trans,trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors. J Enzyme Inhib Med Chem 2012 0.75
47 A linear allergic contact dermatitis to p-tert-butylphenol formaldehyde resin sectorially present in a neoprene orthopedic brace: role of spectroscopy. Dermatitis 2012 0.75
48 Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor. Peptides 2009 0.75
49 Synthesis and proteasome inhibition of N-allyl vinyl ester-based peptides. J Pept Sci 2010 0.75